Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Hu, B; Lin, X; Lee, HC; Huang, XL; Tidwell, RSS; Ahn, KW; Hu, ZH; Jabbour, E; Verstovsek, S; Ravandi, F; Garcia-Manero, G; Kharfan-Dabaja, MA; Hossain, NM; Marks, DI; Kamble, RT; Inamoto, Y; Kindwall-Keller, T; Saad, A; Litzow, MR; Savani, BN; Hale, GA; Bacher, U; Gerds, AT; Liesveld, JL; Ustun, C; Olsson, RF; Daly, A; Grunwald, MR; Solh, M; DeFilipp, Z; Aljurf, M; Wirk, B; Akpek, G; Nishihori, T; Cerny, J; Seo, S; Hsu, JW; Champlin, R; de Lima, M; Alyea, E; Popat, U; Sobecks, R; Scott, BL; Kantarjian, H; Cortes, J; Saber, W

Cortes, J (corresponding author), Georgia Canc Ctr, 1410 Laney Walker Rd,CN2222, Augusta, GA 30912 USA.; Saber, W (corresponding author), Med Coll Wisconsin, 9200 W Wisconsin Ave,Suite,C5500, Milwaukee, WI 53226 USA.

LEUKEMIA & LYMPHOMA, 2020; 61 (12): 2811

Abstract

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residu......

Full Text Link